Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Breast Cancer in Pregnancy (BCP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by German Breast Group.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
University Hospital, Frankfurt
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT00196833
First received: September 12, 2005
Last updated: May 24, 2012
Last verified: July 2009

September 12, 2005
May 24, 2012
April 2003
April 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00196833 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Breast Cancer in Pregnancy
Prospective and Retrospective Register Study of the German Breast Group (GBG) for Diagnosis and Treatment of Breast Cancer in Pregnancy

Women who were diagnosed with breast cancer during their pregnancy may be registered in this trial.

Data is collected on the foetal outcome 4 weeks after delivery, maternal outcome of pregnancy as well as the breast cancer therapy applied (treatment, response to chemotherapy, type of surgery), diagnostic procedures applied (palpation, US, mammogram) and the outcome of mother and child after 5 years of therapy.

Breast cancer is the most common cancer malignancy in women of childbearing age after the age of 25 years. Since the incidence of breast cancer under the age of 40 is increasing, and women tend to delay pregnancy into later reproductive years, the coincidence of pregnancy and breast cancer is increasing. About 1 in 1,000 pregnancies is complicated by breast cancer. Nevertheless, little is known about the right therapy for the mother and the unborn child. We are therefore carrying out a trial, collecting prospective and retrospective data about pregnant women, with histological confirmed breast cancer. Data on the biology of the tumour and placenta tissues is also collected. The anonymous data is collected in a database.

Observational
Not Provided
Not Provided
Retention:   Samples With DNA
Description:

Tumour and placenta specimens are collected

Non-Probability Sample

Women with histologically confirmed breast cancer during pregnancy.

Breast Cancer
Not Provided
Not Provided
Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K, Linn SC, Schlehe B, Gziri MM, Westenend PJ, Müller V, Heyns L, Rack B, Van Calster B, Harbeck N, Lenhard M, Halaska MJ, Kaufmann M, Nekljudova V, Amant F. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012 Sep;13(9):887-96. doi: 10.1016/S1470-2045(12)70261-9. Epub 2012 Aug 16.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
April 2014
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women with histologically confirmed breast cancer during pregnancy.
  • Informed consent for data and specimen collection.

Exclusion Criteria:

  • Diagnosis of breast cancer outside the period of pregnancy.
Female
Not Provided
No
Contact: Sibylle Loibl, PD.MD +49 6102-7480- ext 426 Sibylle.Loibl@GermanBreastGroup.de
Germany
 
NCT00196833
GBG 29, BIG 2-03
No
German Breast Group
German Breast Group
University Hospital, Frankfurt
Principal Investigator: Sibylle Loibl, PD.MD German Breast Group
German Breast Group
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP